torsemide has been researched along with Disease Exacerbation in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balsam, P; Crespo-Leiro, MG; Drożdż, J; Filipiak, KJ; Grabowski, M; Kapłon-Cieślicka, A; Kowalik, R; Maggioni, AP; Marchel, M; Opolski, G; Ozierański, K; Peller, M; Tymińska, A; Wancerz, A | 1 |
| Ding, GL; Guo, SL; Han, LN; Lin, XM; Shi, XM; Yang, LM; Zang, CB | 1 |
| Chiswell, K; Fiuzat, M; Givertz, MM; McKendry, C; Mentz, RJ; Metra, M; O'Connor, CM; Teerlink, JR; Velazquez, EJ; Voors, AA | 1 |
| Aizawa, Y; Kodama, M; Ma, M; Palaniyandi, SS; Suzuki, K; Veeraveedu, PT; Watanabe, K; Yamaguchi, K | 1 |
| Décorps, M; Devoulon, P; Dupeyre, R; Le Bars, E; Loubinoux, I; Massarelli, R; Méric, P; Pinard, E; Rémy, C; Roussel, S | 1 |
1 trial(s) available for torsemide and Disease Exacerbation
| Article | Year |
|---|---|
Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial.
Topics: Aged; Disease Progression; Diuretics; Dose-Response Relationship, Drug; Europe; Female; Follow-Up Studies; Furosemide; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Sulfonamides; Survival Rate; Time Factors; Torsemide; Treatment Outcome | 2015 |
4 other study(ies) available for torsemide and Disease Exacerbation
| Article | Year |
|---|---|
Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology.
Topics: Aged; Disease Progression; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Poland; Recovery of Function; Registries; Risk Factors; Sodium Potassium Chloride Symporter Inhibitors; Time Factors; Torsemide; Treatment Outcome | 2019 |
Torasemide reduces dilated cardiomyopathy, complication of arrhythmia, and progression to heart failure.
Topics: Aged; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Disease Progression; Diuretics; Echocardiography, Doppler, Color; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Incidence; Male; Middle Aged; Prognosis; Sulfonamides; Torsemide; Treatment Outcome | 2014 |
Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy.
Topics: Animals; Atrial Natriuretic Factor; Body Weight; Cardiomyopathy, Dilated; Collagen Type III; Disease Progression; Diuretics; Heart Failure; Male; Matrix Metalloproteinase 9; Myocarditis; Myocardium; Rats; Rats, Inbred Lew; RNA, Messenger; Sulfonamides; Torsemide; Transforming Growth Factor beta1; Ventricular Function, Left | 2008 |
Delayed progression of cytotoxic oedema in focal cerebral ischemia after treatment with a torasemide derivative: a diffusion-weighted magnetic resonance imaging study.
Topics: Animals; Antihypertensive Agents; Brain Ischemia; Disease Progression; Edema; Magnetic Resonance Imaging; Male; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors; Torsemide | 1996 |